Patient groups representing millions of Americans with pre-existing conditions filed an amicus curiae or friend of the court brief in the U.S. District Court case, Texas v. United States, citing the devastating impact patients would face should the court side with plaintiffs and move to invalidate the Affordable Care Act.
The Department of Justice (DOJ) announced last night it will not defend several critical patient protections in the health law and instead is arguing to end them. If successful, the case could leave millions of Americans with serious illnesses unable to obtain health care coverage.
Today Virginia governor Ralph Northam signed into law a state budget that extends health care coverage to an estimated 400,000 low-income Virginians through the Medicaid program. Virginia is now the 33rd state, in addition to Washington, D.C., to accept federal funding to provide health insurance coverage to adults earning less than 138 percent of the federal poverty level—just under $17,000 a year for a single adult. As part of the expansion, Virginia will require Medicaid recipients attend school, work, partake in job training or engage in some kind of community engagement for upwards of 80 hours a month in order to receive benefits. This requirement could pose significant challenges to cancer patients and survivors.
The American Cancer Society Cancer Action Network (ACS CAN), Friends of Cancer Research (FOCR), and the National Organization for Rare Disorders (NORD) along with more than 100 advocacy groups representing millions of patients submitted a letter to Members of the House of Representatives strongly opposing the Senate Right-to-Try Act (S. 204).
Washington, D.C. – May 22, 2018 – The House of Representatives passed legislation today that, if signed into law, will create a process for accessing experimental drugs without including proper patient protections. The Senate Right-to-Try legislation (S.
Washington, D.C. - Leading health care companies and organizations representing patients, providers, laboratories and diagnostic manufacturers called on Senate and House leaders to advance legislation that would reform and modernize the process for bringing innovative diagnostics
I am gravely concerned about a bill being considered by the Minnesota legislature that would add unnecessary challenges to the mountain cancer patients have to climb.
More than 100 organizations representing millions of patients, providers and consumers joined together in letters and formal comments to Congressional leadership and federal agencies urging the withdrawal of a proposed rule on short-term, limited duration insurance plans (STLD).
oday the American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Department of Health and Human Services (HHS) on proposed changes to rules governing short-term, limited duration insurance plans (STLD). The comments detail how the proposed rule could divide the individual insurance market and significantly weaken patient protections, leaving cancer patients and survivors with few meaningful or affordable coverage choices.
The U.S. House of Representatives today passed an FY 18 federal budget, which includes; a $3 billion increase for medical research at the National Institutes of Health (NIH)—the largest such funding increase in 15 years; and a $275 million increase for the National Cancer Institute (NCI).